

Leading the diagnostics of
front-of-the eye diseases
by offering true
multiparameter analysis of
the tear fluid

An ideal drug
companion
diagnostic

Enables
personalized
disease treatment

Dry Eye First: A Multifactorial Disease

Difficult to diagnose and treat

48%

of Americans
(approximately 340 million people)
regularly experience dry eye
symptoms

1 in 3


visits to ophthalmic clinics in
the US are related
to dry eye symptoms

~ 70

companies are in
development of
new dry eye treatments


Existing Diagnostic Tools: Nonspecific & Conflicting

Current
diagnostics
measure only a
single parameter
from this
multifactorial
syndrome




The Solution to a Multifactorial Diagnosis:

Multiparameter
analysis of tear fluid:
Several tear
components
analyzed and with
algorithm combined
into one result in
minutes




Could be used as a Companion Diagnostic


Specifically tailored to identify responder's population
for a specific treatment



• Numerous new DES
treatments in
development. Many
failures in the past



• Each patient is tested
before and after treatment
• Uses a battery of different
parameters



• Better patient selection
• Improved chances to study
success
• Reimbursable
• Commercial differentiation

How it works

Collector

- Microfluidic device
- Collects 1 µL of tear fluid
- Dilutes 1:200
- Dispense single drops into the cassettes


Blister (part of the collector)

- Unique liquid composition
- Comprised of aluminum
- Completely sealed

Cassette

- Multichannel
- Fluent flow of the liquid

Watch Movie



Milestones

Major study to commence in India Q3/2021

2015

1st clinical study
200 subjects
Strong correlation to
benchmark tests

2016

2nd US
clinical study
74 subjects
87% sensitivity
86% specificity

2017

3rd clinical
study
82 subjects
Kit finalization
and testing

2019

CE mark approval
US & Europe
Patents Granted

2020

1. Signed a significant
clinical study and option
agreement with large
Pharma company
(follow-up over 6
months – to understand
the disease progression)
2. Raised money from
Strategic Investor
Elcam Medical



- Top International Manufacturer
- Elcam to invest ~ \$3M USD
- Investment at ~ \$18.5M USD post money valuation

Management




Yaacov Michlin
Chairman

CEO at BioLight (TASE: BOLT)
Former CEO BrainsWay
(NASDAQ, TASE: BWAY)
Co-Chairman at IATI
(Israel Advanced Technology Industries)



Dr. Eran Eilat, MD, PhD.
CEO

A serial entrepreneur who has founded
several biotechnology
and medical device companies




Dr. Amos Sommer, PhD
COO

An experienced lateral flow expert
Led R&D in Alere Inc.
(Organics)

Future

AI-driven system for Various Front of the eye Diseases



Thank You!